Could a traditional chinese medicine help stop lung scarring?
NCT ID NCT07319598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether tetrandrine tablets can improve lung function in people with interstitial lung disease caused by connective tissue disease (like lupus or scleroderma). One hundred adults will receive either tetrandrine or a placebo for 24 weeks, alongside their usual treatments. The main goal is to see if the drug helps preserve breathing capacity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tetrandrine tablets
What this could lead to
If it works, this could provide a new treatment option to slow lung damage and improve breathing in people with connective tissue disease-related lung scarring.
What could go wrong
This is a small, early-phase (Phase 4) study with only 100 participants. The drug may not improve lung function more than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••